title: [Arteriosclerosis and vascular calcification in chronic kidney disease (CKD) patients].
abstract: Chronic kidney disease (CKD) patients are belonging to high risk patients to atherosclerosis with vascular calcification. These patients are well recognized advanced arteriosclerosis with vascular medial calcification, with high risk of cardiovascular death. With basic investigated results, the mechanism of vascular calcification is making clear. A lot of various factors which participate in calcification have been specified. Especially, in long term dialysis patients, the very high grade vascular calcification with advanced atherosclerosis is common with calcium/phosphate/PTH and skeletal problem. This CKD related metabolic bone disorder (CKD-MBD) highly induced and progressed vascular calcification. Participates in vascular calcification. It is extremely important in order to prevent vascular calcification to manage serum phosphorus, serum calcium and parathyroid function within the suitable range. In addition, hyperphosphatemia is becoming the powerful risk factor for patients' survival. The new powerful phosphate binder is developing. The beneficial effect of the new agent on patients' survival is now focused.
authors.affiliation: Saiseikai Wakayama hospital, Division of Dialysis Center.
authors.forename: Yuri
authors.initials: Y
authors.lastname: Masho
authors.forename: Takashi
authors.initials: T
authors.lastname: Shigematsu
mesh_terms: D001161:Arteriosclerosis / Q000209:etiology* / Q000517:prevention & control*; D001851:Bone Diseases, Metabolic / Q000209:etiology / Q000517:prevention & control; D002114:Calcinosis / Q000209:etiology* / Q000517:prevention & control*; D002118:Calcium / Q000097:blood; D002614:Chelating Agents / Q000008:administration & dosage; D016757:Death, Sudden, Cardiac / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D010281:Parathyroid Hormone / Q000097:blood; D010758:Phosphorus / Q000097:blood; D011073:Polyamines / Q000008:administration & dosage; D044169:Receptors, Calcium-Sensing / Q000819:agonists; D006435:Renal Dialysis / Q000009:adverse effects; D012307:Risk Factors; D000069603:Sevelamer
chemical_list: D002614:Chelating Agents; D010281:Parathyroid Hormone; D011073:Polyamines; D044169:Receptors, Calcium-Sensing; D010758:Phosphorus; D000069603:Sevelamer; D002118:Calcium